Summary
The nondystrophic myotonias are a heterogeneous set of rare diseases that demonstrate clinical myotonia, electrical myotonia, or both. These disorders are distinguished from myotonic dystrophy type 1 (DM-1), the more recently described proximal myotonic myopathy/myotonic dystrophy type 2 (PROMM/DM-2), and proximal myotonic dystrophy (a variant of DM-2) by characteristic clinical features, lack of abnormal nucleotide repeat expansions in the DM-1 and DM-2 genes, lack of cataracts and endocrine disturbances, and absence of significant histopathology in the muscle biopsy. The present article reviews each of the nondystrophic myotonias by exploring the unique clinical features, electrodiagnostic findings, diagnostic criteria, gene mutations, and response to pharmacologic therapy. These diseases are divided into those with chloride channel dysfunction (the myotonia congenita disorders) and those with sodium channel dysfunction (paramyotonia congenita, potassium-aggravated myotonia, and hyperkalemic periodic paralysis with myotonia). The variants that occur in each of these conditions are commented on. The differentiating features of the nondystrophic myotonias are summarized, and their predominant clinical, electrodiagnostic, and genetic characteristics are tabulated. For a comprehensive review of pertinent research and studies with application to diagnosis and treatment of individuals with nondystrophic myotonic disorders, the present article is best read in the context of other articles in this issue, especially those on ion channel physiology (Cannon) and pharmacology (Conte-Camerino), and on hyperkalemic periodic paralysis (Lehmann-Horn).
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Hudson AJ, Ebers GC, Bulman DE. The skeletal muscle sodium and chloride channel diseases. Brain 1995;118: 547–563.
Preston DC, Shapiro BE. Electromyography and neuromuscular disorders. Boston: Butterworth-Heinemann; 1998.
Streib EW. AAEE minimonograph #27: Differential diagnosis of myotonic syndromes. Muscle Nerve 1987;10: 603–615.
Kimura J. Electrodiagnosis in diseases of nerve and muscle: principles and practice. 2nd ed. Philadelphia: Davis; 1989.
Moxley RT 3rd. Approach to the evaluation of myotonia [oral presentation]. Presented at the 55th Annual Meeting, American Academy of Neurology; March 29–April 5, 2004; Honolulu, HI.
Dumitru D, Amato AA. Introduction to myopathies and muscle tissue’s reaction to injury. In: Dumitru D, Amato AA, Zwarts MJ, editors. Electrodiagnostic medicine. 2nd ed. Philadelphia: Hanley & Belfus; 2002: 1229–1264.
Amato AA, Dumitru D. Hereditary myopathies. In: Dumitru D, Amato AA, Zwarts MJ, editors. Electrodiagnostic medicine. 2nd ed. Philadelphia: Hanley & Belfus; 2002: 1265–1370.
Moxley RT, Tawil R. Channelopathies: myotonic disorders and periodic paralysis. In: Swaiman KF, Ashwal S, Ferriero DM, editors. Pediatric neurology: principles and practice. 4th ed. Philadelphia: Mosby; 2006: 2085–2109.
Rudel R, Lehmann-Horn F. Paramyotonia, potassium-aggravated myotonias and periodic paralyses. 37th ENMC International Workshop, Naarden, The Netherlands, 8–10 December 1995. Neuromuscul Disord 1997;7: 127–132.
Russell SH, Hirsch NP. Anaesthesia and myotonia. Br J Anaesth 1994;72: 210–216.
Ricker K, Rudel R, Lehmann-Horn F, Kuther G. Muscle stiffness and electrical activity in paramyotonia congenita. Muscle Nerve 1986;9: 299–305.
Ricker K, Haass A, Rudel R, Bohlen R, Mertens HG. Successful treatment of paramyotonia congenita (Eulenburg): muscle stiffness and weakness prevented by tocainide. J Neurol Neurosurg Psychiatry 1980;43: 268–271.
Moxley RT 3rd, Ricker K, Kingston WJ, Bohlen R. Potassium uptake in muscle during paramyotonic weakness. Neurology 1989; 39: 952–955.
Gutmann L, Phillips LH 2nd. Myotonia congenita. Semin Neurol 1991;11: 244–248.
Davies NP, Hanna MG. Neurological channelopathies: diagnosis and therapy in the new millennium. Ann Med 1999;31: 406–420.
Shapiro B, Ruff R. Disorders of skeletal muscle membrane excitability: myotonia congenita, paramyotonia congenita, periodic paralysis, and related disorders. In: Katirji B, Kaminski HJ, Preston DC, Ruff RL, Shapiro BE, editors. Neuromuscular disorders in clinical practice. Boston: Butterworth-Heinemann; 2002: 987–1020.
Colding-Jørgensen E. Phenotypic variability in myotonia congenita. Muscle Nerve 2005;32: 19–34.
Becker PE, Knussmann R, Kuhn E, contributors; Passarge MF, translator. Myotonia congenita and syndromes associated with myotonia. Topics in Human Genetics 3. Stuttgart: Georg Thieme; 1977: 1–178.
Lacomis D, Gonzales JT, Giuliani MJ. Fluctuating clinical myotonia and weakness from Thomsen’s disease occurring only during pregnancies. Clin Neurol Neurosurg 1999;101: 133–136.
Lehmann-Horn F, Mailander V, Heine R, George AL. Myotonia levior is a chloride channel disorder. Hum Mol Genet 1995;4: 1397–1402.
Wagner S, Deymeer F, Kurz LL, et al. The dominant chloride channel mutant G200R causing fluctuating myotonia: clinical findings, electrophysiology, and channel pathology. Muscle Nerve 1998;21: 1122–1128.
Lehmann-Horn F, Rudel R. Hereditary nondystrophic myotonias and periodic paralyses. Curr Opin Neurol 1995;8: 402–410.
Duffield M, Rychkov G, Bretag A, Roberts M. Involvement of helices at the dimer interface in C1C-1 common gating. J Gen Physiol 2003;121: 149–161.
Brooke MH. Disorders of skeletal muscle. In: Bradley WG, Daroff RB, Fenichel GM, Marsden CD, editors. Neurology in clinical practice. 3rd ed. Boston: Butterworth-Heinemann; 2003: 2187–2235.
Kwiecinski H, Ryniewicz B, Ostrzycki A. Treatment of myotonia with antiarrhythmic drugs. Acta Neurol Scand 1992;86: 371–375.
Streib EW. Paramyotonia congenita. Semin Neurol 1991;11: 249–257.
Eulenburg A. Über eine familiäre, durch 6 Generationen verfolgbare Form kongenitaler Paramyotonie. Neurol Zentralbl 1886;5: 265–272.
Surtees R. Inherited ion channel disorders. Eur J Pediatr 2000; 159(Suppl 3): S199-S203.
Rudel R, Ricker K, Lehmann-Horn F. Genotype-phenotype correlations in human skeletal muscle sodium channel diseases. Arch Neurol 1993;50: 1241–1248.
Ptacek LJ, Johnson KJ, Griggs RC. Genetics and physiology of the myotonic muscle disorders. N Engl J Med 1993;328: 482–489.
Brungger U, Kaeser HE. Paramyotonia congenita without cold paralysis and myotonia levior: a genetic and clinical study. Eur Neurol 1977;15: 2–4.
Ricker K, Lehmann-Horn F, Moxley RT 3rd. Myotonia fluctuans. Arch Neurol 1990;47: 268–272.
Ricker K, Moxley RT 3rd, Heine R, Lehmann-Horn F. Myotonia fluctuans: a third type of muscle sodium channel disease. Arch Neurol 1994;51: 1095–1102.
Colding-Jørgensen E, Duno M, Vissing J. Autosomal dominant monosymptomatic myotonia permanens. Neurology 2006;67: 153–155.
Trudell RG, Kaiser KK, Griggs RC. Acetazolamide-responsive myotonia congenita. Neurology 1987;37: 488–491.
Ptacek LJ, Tawil R, Griggs RC, Storvick D, Leppert M. Linkage of atypical myotonia congenita to a sodium channel locus. Neurology 1992;42: 431–433.
Hanna MG, Stewart J, Schapira AH, Wood NW, Morgan-Hughes JA, Murray NM. Salbutamol treatment in a patient with hyperkalaemic periodic paralysis due to a mutation in the skeletal muscle sodium channel gene (SCN4A). J Neurol Neurosurg Psychiatry 1998;65: 248–250.
Tawil R, McDermott MP, Brown R Jr, et al. Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis. Ann Neurol 2000;47: 46–53.
Streib EW. Paramyotonia congenita: successful treatment with tocainide; clinical and electrophysiologic findings in seven patients. Muscle Nerve 1987;10: 155–162.
Sansone V, Links T, Meola G, Rose MR. Treatment for periodic paralysis. (Protocol.) Cochrane Neuromuscular Disease Group. Cochrane Database Syst Rev 2004;3: CD005045 (updated 2006;2).
Barchi RL. Myotonia: an evaluation of the chloride hypothesis. Arch Neurol 1975;32: 175–180.
Kennedy F, Wolf A. Experiments with quinine and prostigmine in the treatment of myotonia and myaesthenia. Arch Neurol Psychiatry 1937;37: 68–74.
Berardinelli A, Gorni K, Orcesi S. Response to carbamazepine of recessive-type myotonia congenita. Muscle Nerve 2000;23: 138–139.
Gerst JW, Brumback RA, Staton RD. Lithium-induced improvement of myotonia. J Neurol Neurosurg Psychiatry 1984;47: 1044–1046.
Brown RH Jr. Ion channel mutations in periodic paralysis and related myotonic diseases. Ann N Y Acad Sci 1993;707: 305–316.
Ptacek LJ, Tawil R, Griggs RC, et al. Sodium channel mutations in acetazolamide-responsive myotonia congenita, paramyotonia congenita, and hyperkalemic periodic paralysis. Neurology 1994;44: 1500–1503.
Founder E, Arzel M, Sternberg D, et al. Electromyography guides toward subgroups of mutations in muscle channelopathies. Ann Neurol 2004;56: 650–661.
Rosenfeld J, Sloan-Brown K, George AL Jr. A novel muscle sodium channel mutation causes painful congenital myotonia. Ann Neurol 1997;42: 811–814.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Heatwole, C.R., Moxley, R.T. The nondystrophic myotonias. Neurotherapeutics 4, 238–251 (2007). https://doi.org/10.1016/j.nurt.2007.01.012
Issue Date:
DOI: https://doi.org/10.1016/j.nurt.2007.01.012